PennyPerformers.com: "Penny Stocks that Perform" picks are: BZYR, GLOW, IXSBF, STVI, TADF

Jan 13, 2009 (M2 PRESSWIRE via COMTEX) -- TADFE | Quote | Chart | News | PowerRating -- Pennyperformers.com "Penny Stocks that Perform" picks are: The Burzynski Research Institute, Inc. (OTCBB: BZYR), Glowpoint, Inc. (OTCBB: GLOW), InNexus Biotechnology Inc. (OTCBB: IXSBF), SNAP Interactive, Inc. (OTCBB: STVI), Tactical Air Defense Services, Inc. (OTCBB: TADF)...and Proudly Introducing Proprietary Push Technology (PPT).

The Newest and Revolutionary Technology for Increasing Investor Visability.

REAL Awareness for REAL Companies.

Click below for a full demonstration.

http://newmediaadvisors.info/newmedia.swf

Sign-up for our FREE Stock Alerts AND NEWSLETTER at www.pennyperformers.com

Jan 13, 2009 -- The Burzynski Research Institute, Inc. (OTCBB: BZYR | Quote | Chart | News | PowerRating) (BRI) today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) that enables the company to move forward immediately with a pivotal Phase III clinical trial of combination antineoplaston therapy plus radiation therapy in patients with newly-diagnosed, diffuse, intrinsic brainstem glioma. Antineoplaston therapy (ANP) uses a synthetic version of naturally occurring peptides and amino acid derivatives found in the human body to target and control cancer cells without destroying normal cells. The agreement was made under the FDA's Special Protocol Assessment (SPA) procedure and means that the design and planned analysis of the Phase III study is acceptable to support a regulatory submission seeking new drug approval.

"We are very pleased by our agreement with the FDA to move forward with a confirmatory study on a type of tumor that has shown itself to be highly treatment resistant and challenged further by severely limited treatment options and clinical trials that could expand and discover new, efficacious therapies," said Stanislaw R. Burzynski, M.D., Ph.D. "The SPA agreement puts antineoplaston therapy further down a straight path to regulatory approval, enabling the kind of study that should prove its merits as another option to cancer management."

"BRI has reached this important milestone independently without financial backing from the government, and without a major pharmaceutical partner--a unique accomplishment in the oncology field. From inception, we have been committed to developing a targeted gene therapy option that is less aggressive on the body than conventional therapies and have made considerable progress on the steps mandated by the FDA to bring a new drug to a patient community and cancer type that has unmet needs."

About the Phase III study

The primary objective of this randomized study is to compare overall survival of children with newly-diagnosed diffuse intrinsic brainstem glioma (DBSG) who receive combination antineoplaston therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] plus radiation therapy (RT) versus RT alone.

DBSG are considered to be one of the most difficult types of cancer to treat. It combines highly malignant characteristics with the very difficult location of the brainstem. DBSG are inoperable because they involve most of the brainstem (diffuse and intrinsic). The number of children in the U.S. with brainstem gliomas is approximately 660. Absent treatment, the survival rate from time of diagnosis is six months or less.

At present, there are no standard curative treatments for the disease. RT is the only treatment that may slow its progress, but at two years 93% of children with this type of cancer die, and none of them survive for five years. Other conventional treatments such as chemotherapy have generally been tried in clinical trials but are shown to be ineffective. There are no pharmacological treatments approved for DBSG at this time.

Burzynski Research Institute, Inc. is a biopharmaceutical company committed to developing treatment for cancer based on genomic and epigenomic principles.

Research and development efforts are focused on basic ANP research and 19 Phase II clinical trials.

Jan 13, 2009 -- Glowpoint, Inc. (OTCBB: GLOW), a leading provider of advanced video communications solutions, is pleased to announce that Glowpoint CEO Michael Brandofino was selected as the 2008 winner of TeleSpan's Pace Award, which honors teleconferencing professionals who have made significant contributions to the industry.

The Pace Award is presented annually by TeleSpan's publisher, Elliot Gold, who is widely regarded as a leading teleconferencing industry analyst, and who is often a quoted source in the video communications industry. Mr. Gold commented that Mr. Brandofino is "not only a technologist, but a visionary." Gold also cited that Brandofino has run a company that is now "approaching profitability" and is "regaining the trust of the analysts." Gold's announcement can be viewed at http://www.glowpoint.com/Downloads/Electronic%20Telespan%201.09.pdf

Mr. Brandofino said: "Receiving this award from my peers in the industry is especially rewarding. I am pleased to accept this award on behalf of myself and the entire Glowpoint team, whose tremendous effort in 2008 has well positioned us for a strong 2009 and beyond."

TeleSpan was founded in 1981 as an industry analysis firm covering the field of video communications. The firm publishes annual reports covering trends in the industry, in addition to a frequent newsletter that is widely read by industry professionals, telepresence users, and general video communication users.

About Glowpoint

Glowpoint, Inc. is a leading provider of advanced video communications solutions. Glowpoint's advanced and robust suite of telepresence and video communications solutions are enabling organizations to communicate with each other over disparate networks and technology platforms. Glowpoint supports thousands of video communications system in 35 countries with its 24/7 video management services, powering major broadcasters, Fortune 500 companies, as well as global carriers and video equipment manufacturers and their customers around the world.

Jan. 13, 2009 -- InNexus Biotechnology Inc., (OTCBB: IXSBF | Quote | Chart | News | PowerRating) (TSX VENTURE: IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces the completion of a large scale primate study confirming effectiveness and safety of its lead candidate DXL625 (CD20). The Company also announced that it has scheduled a meeting with the United States Food and Drug Administration (FDA) during the first half of 2009 to discuss the design of a clinical study.

"This study confirms that DXL625 is specific to the CD20 antigen present on NHL tumor cells and is a major milestone in our plan for clinical and commercial success," said Jeff Morhet, CEO and Chairman of InNexus. "This success paves the way for the filing of an IND and commencement of clinical trials of DXL625 in the near future." Complete results from this study are being compiled and will be presented at the annual scientific meeting of the American Association for Cancer Research (AACR) this spring.

InNexus' recently completed study was designed to confirm DXL625's in vivo safety and efficacy. The candidate was effective in completely eliminating all lymphocytes with a CD20 marker within hours at the lowest dose tested. No adverse events were seen even at a dose 100-fold higher than the lowest dose. The CD20 marker is the same as that found on tumors cells in patients with Non-Hodgkins Lymphoma patients. Previous studies have shown that DXL625 has greater potency as compared to existing therapeutic antibodies.

Pre-clinical data show that DXL625 has a safety profile equal to Rituxan(R) when evaluated in the same validated model. The preclinical study was conducted with a single injection, which confirms the remarkable potency of DXL625. In addition, the study showed no difference in immunogenicity as compared to Rituxan(R). Prior assessment of potential cross-reactivity using a limited panel of human tissue slices has revealed no off-target reactions.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics.

Jan 13, 2009 -- SNAP Interactive, Inc. ("SNAP" or the "Company") (OTCBB: STVI), a leading provider of online dating applications for social networking websites, announced today that it has more than doubled its programming capacity since September 30, 2008 and added highly specialized technical acumen in growing its already experienced and skilled team.

"As highly cost-conscious operators, we do not assume significant added expenses unless there is substantial business justification for the move," stated SNAP President and CEO Clifford Lerner. "By strategically growing our programming team we can now pursue next generation opportunities that position us for future growth and industry leadership. With our expanded capacity and technical strength we can be at the forefront of mobile dating applications, and we now have the resources necessary to further execute growth and monetization strategies across our existing Social Networks footprint. With a tightly managed cost basis we have built a base in excess of 16 million users; with this judicious investment in infrastructure development we can now realize the value of this user base and help pioneer the next phase of the Social Networking revolution.

"We maintain a long-term perspective for our business, and we believe very strongly a development capacity increase at this time is both 100% necessary for the execution of our business plan and best positions us to take advantage of significant potential opportunities to come."

About SNAP Interactive, Inc.

Incorporated in Delaware and headquartered in New York, SNAP Interactive, Inc. is a leading provider of online dating applications for social networking websites. SNAP has developed two dating applications built on Facebook(R) Platform which have in excess of 16 million installations, and has also launched dating applications on MySpace Developer Platform & Hi5 Developer Platform. Our applications are called 'Are You Interested,' 'Meet New People,' and 'Flirt With Me.'

Jan 13, 2009 -- Tactical Air Defense Services, Inc. (OTCBB: TADF), a military contractor that offers air combat and pilot training, mid-air refueling, specialty aerial services, ground-threat support, and aerial fire-fighting services, to the U. S. and Foreign Militaries and to other Federal and State Agencies, is pleased to announce that it has received shareholder approval, at our annual meeting of shareholders, to change our name to Aerogroup Incorporated and to enact a Reverse Stock-Split of 1-for-10, subject to FINRA notification for assignment of an ex-dividend date.

The original Aerogroup Incorporated, a private company with which TADF executed an asset purchase agreement in 2006, is a recognized leader in air combat training, having conducted training for the U.S. Navy, and the Canadian, British, Dutch, and Belgian Air Forces. Mark Daniels, CEO and founder of both TADF and Aerogroup states, "We believe the name change to Aerogroup and the Reverse Stock-Split will better reflect our operational experience, our execution capabilities, and the business infrastructure we have built over the last few years, and will lead to increased shareholder value."

The Company anticipates the Name Change and Reverse Stock-Split becoming effective within the next few weeks.

About PennyPerformers.com

PennyPerformers.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

Penny Performers email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Penny Performers Report home page at www.PennyPerformers.com and select the "join now" button.

Join us at www.PennyPerformers.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. PennyPerformers.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyPerformers.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. PennyPerformers.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), PennyPerformers.com is owned and operated by PennyPerformers.com. Neither PennyPerformers.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since PennyPerformers.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in PennyPerformers.com statements and opinions and such statements and opinions cannot be considered independent. PennyPerformers.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. PennyPerformers.com services are often paid for using free-trading shares. PennyPerformers.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: www.PennyPerformers.com/disclaimer.htm

CONTACT: Pennyperformers.com e-mail: info@pennyperformers.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index